Rivaroxaban for patients with coronary dissection after drug-coated balloon

angioplasty : A Randomized Controlled Trial

Kaiyuan Liu, MD^a, Quan Guo, MD^a, Shi Qingbo, MD^a, Ming Nie, MD^a, Haosen Yu, MD^a, Zhiwen Zhang^a, MD, Muwei Li, MD^a.

^aDepartment of Cardiology, Department of Coronary Heart Disease of Central China Fuwai Hospital, Henan Key Laboratory for Coronary Heart Disease, Central China Fuwai Hospital of Zhengzhou University, No. 1 Fuwai Road, Zhengzhou, Henan Province, China.

Funding: This work was supported by National Key Research and Development Program of China (2022YFC3602400,2022YFC3602404), Henan Medical Science and Technology Public Relations Joint Construction Project (LHGJ20220108), National Natural Science Foundation of China (82270474). The funding source did not influence any part of the submitted work, including the study design, collection, analysis, interpretation of data, the writing of the article, or decision to submit for publication.

Disclosures: All authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Address for correspondence: Dr Muwei Li, Department of Cardiology, Central China Fuwai Hospital of Zhengzhou University, No. 1 Fuwai Road, Zhengzhou, Henan Province, China.

E-mail: lmwei0207@zzu.edu.cn

1

ABSTRACT

Background : After drug-coated balloon (DCB) angioplasty in patients with de novo

coronary lesions, coronary dissections can result in the continuous presence of thrombi within the vessel wall, potentially leading to late luminal loss. Rivaroxaban, a novel oral anticoagulant, may mitigate lumen loss attributable to coronary dissection.

Objectives: This study was conducted to evaluate the effectiveness and safety of low-dose rivaroxaban in improving outcomes for patients with dissections following DCB intervention.

Methods: This trial was a prospective, randomized, controlled study including patients with acute coronary syndrome (ACS) who exhibited non-flow-limiting dissections after DCB angioplasty for de novo coronary lesions. The rivaroxaban group received a standard dual antiplatelet therapy (DAPT) regimen along with 2.5 mg of rivaroxaban twice daily for one month, reverting to DAPT thereafter. The control group was treated with standard DAPT for 6 months. All patients underwent coronary angiography at the 6-month mark. The primary endpoint involved late lumen loss in the target vessel at 6 months, and the primary safety endpoint consisted of bleeding events, as classified according to BARC criteria (types 1-3 or 5). This study has been registered with ClinicalTrials.gov, number NCT05750758.

Results : Out of 140 randomized patients, 137 (69 in the rivaroxaban group, 68 in the

control group) completed the study. Low-dose rivaroxaban was associated with a significant reduction in late lumen loss compared to controls (-0.12 ± 0.56 mm versus 0.14 ± 0.37 mm, P = 0.002). The rivaroxaban group experienced more minor bleeding events (BARC 1-2), though this was not statistically significant (P = 0.059). Clinical outcomes were similar between groups (P = 0.354).

Conclusions : This study demonstrates that the combination of rivaroxaban with dual

antiplatelet therapy shows promise in reducing stenosis and enhancing late lumen expansion in lesions with dissections post-DCB intervention.

Keywords: rivaroxaban; dissection; coronary heart disease; drug-coated balloon angioplasty

Abbreviations: DCB= drug-coated balloon angioplasty; **ACS**= acute coronary syndrome; **BA**= balloon angioplasty; **LLL**= late lumen loss;

Introduction

The drug-coated balloon (DCB) represents a type of medical device coated with anti-vascular intimal hyperplasia drugs. Upon inflation at the diseased vessel site, the balloon contacts the vessel wall's endothelium. The drug is then rapidly released onto the endothelium, disrupting and stretching the vessel wall, inhibiting smooth muscle cell proliferation, and thus reducing restenosis rates without necessitating metallic stent implantation. Evidence has established the safety and efficacy of DCB treatment in various conditions, including in-stent restenosis¹, and bifurcation lesions². There is also an increasing body of evidence supporting the use of DCB in the treatment of de novo lesions, especially in patients with small vessel disease, high bleeding risk, and myocardial infarction³⁻⁶. Also, evidence is growing regarding the efficacy of a DCB-only strategy in treating de novo lesions in large (≥ 2.75 mm) coronary arteries⁷⁻⁹.

The utilization of DCB-only therapy is progressively being adopted in the management of de novo lesions. However, mechanically, DCB function similarly to conventional balloons, and consequently, they inherit some of the primary limitations associated with these devices following angioplasty, specifically coronary dissection and acute recoil.

Dissection is a double-edged sword. Dissections might enhance the contact area between the vessel wall and antiproliferative drugs, promoting drug absorption. Conversely, severe dissections may also lead to the persistence of thrombi within the vessel wall, contributing to late lumen loss post-thrombosis organization or even

3

directly leading to complications like acute myocardial infarction¹⁰. These risks highlight the need for complementary therapeutic strategies to mitigate complications and enhance overall treatment efficacy.

In this context, rivaroxaban, a novel oral anticoagulant, emerges as a promising approach. Studies like ATLAS ACS 2-TIMI 51 and COMPASS have already underscored the efficacy of rivaroxaban in reducing major adverse cardiovascular events (MACE) in coronary heart disease¹¹⁻¹³. This backdrop sets the stage for exploring rivaroxaban's role in patients with coronary dissections post DCB angioplasty.

Taking into consideration the context outlined above, we have formulated this trial with the primary objective of assessing the effects of rivaroxaban for ACS patients with coronary dissection after drug-coated balloon angioplasty. To date, no studies have been conducted in this specific area. We hypothesize that rivaroxaban would improve clinical benefits in patients who retain dissections post-DCB treatment and aim to test this hypothesis in a prospective, randomized, controlled trial.

Materials and Methods

Trial design

The trial followed a prospective, randomized design. It complied with the Declaration of Helsinki and was approved by the New Business and Technology Ethics Committee of Fuwai Central China Cardiovascular Hospital, Zhengzhou University (Zhengzhou, China). We followed the Consolidated Standards of Reporting Trials (CONSORT) checklist¹⁴ to report this study (Supplemental file 1: CONSORT checklist). All participants signed an informed consent form. This study is registered with

ClinicalTrials.gov, number NCT05750758.

Participants

Eligible participants were those: (1) Age \geq 18 years; (2) Acute coronary syndrome (ACS) patients meeting the criteria for percutaneous coronary intervention (PCI); (3) DCB used for de novo target lesions during PCI; (4) Non-flow limited dissection. Exclusion criteria: (1) Age \geq 60 years; (2) Long-term oral anticoagulant treatment; (3) High bleeding risk (meeting the major or minor criteria for high bleeding risk according to Academic Research Consortium)¹⁵; (4) Non-de novo vascular lesions; (5)Severe calcified lesions ; (6) Contraindication to antiplatelet and anticoagulant therapy; (7) Allergy to heparin or contrast agent; (8) Planned elective surgery; (9) Expected life span < 1 year; (10) Need for stent bail out due to intra-procedural complications.

Procedural Technique

The procedure followed the consensus guidelines from international and Asian experts on drug-coated balloons^{3, 16}. Preoperatively, patients received standard dual antiplatelet therapy (DAPT), and intraoperatively, heparin (70-100U/kg) was administered. Coronary angiography was performed following nitroglycerin-induced dilation to obtain optimal target lesion images. Predilation strategies were determined by the operator based on lesion characteristics. Intra-vascular ultrasound (IVUS) and rotational atherectomy were employed as needed. In cases of flow-limiting dissection after predilation, PCI using a drug-eluting stent (DES) was recommended without using a DCB. DCBs used were SeQuent (B. Braun, Germany) and adhered to standard operating protocols. The DCB was inflated for 30 to 60 s at nominal pressure. After

using a DCB, a final assessment was undertaken at least 5 minutes after administering a bolus of intracoronary vasodilator, in order to catch acute vessel recoil. In the event of vessel recoil, bailout stent implantation was considered. TIMI flow and dissection status were recorded immediately post-procedure.

Patients with any residual coronary dissection after DCB use entered the current analysis. It is our habit not to stent coronary dissections of type A to C (National Heart, Lung, and Blood Institute [NHBLI] classification system for intimal tears)¹⁷ with Thrombolysis In Myocardial Infarction (TIMI) flow grade 3.

Randomization and interventions

Randomization (1:1 ratio) was performed by an independent statistician using a computer-generated list. The rivaroxaban group received a standard DAPT(Aspirin 100mg QD + Ticagrelor 90mg BID) regimen along with 2.5 mg of rivaroxaban twice daily for one month, reverting to DAPT for 5 months thereafter. The control group was treated with standard DAPT for 6 months. Angiographic follow-up was conducted at 6 months post-procedure.

Endpoints

The primary endpoint was LLL at 6 months, and the secondary endpoint was target vessel failure (TVF, composed of cardiac death, target vessel myocardial infarction, target vessel revascularization, and target vessel thrombosis)¹⁸. The main safety endpoint was bleeding as defined by the BARC 1-3 or 5 criteria¹⁹.

Follow Up and Data Analysis

Telephone follow-up assessments were conducted at 1, 3, and 6 months

postoperatively to document cardiovascular medication usage, clinical status, and adverse events, with a specific emphasis on bleeding events. All bleeding and ischemic events were independently adjudicated by a Clinical Events Committee^{18, 19}. Subsequently, all patients underwent angiographic follow-up with quantitative coronary assessment after 6 months. The assessment of quantitative analysis for angiographic data was conducted by an independent core laboratory (Key Laboratory of Coronary Artery Imaging Medicine of Henan Province, Zhengzhou, China), utilizing the CAAS research system (Version 5.10, Pie Medical Imaging B.V., Maastricht, The Netherlands). The laboratory remained uninformed about the data grouping during the analysis phase, adhering to a blinded methodology to ensure impartiality in the evaluation process. Analyses were conducted on angiograms with identical projections before, after interventions, and at the angiographic follow-up. All measurements were performed on cineangiograms recorded after 200 mg of intracoronary nitroglycerin administration. Identical projections were used for each comparison. Measurements were taken for minimum luminal diameter (MLD), maximal diameter stenosis (DS%), reference vessel diameter (RVD), lesion length, binary restenosis, and persistence of dissection (NHLBI classification), and late luminal enlargement (LLE) or late luminal loss (LLL). LLL was defined as a decrease in the minimum luminal diameter at the follow-up compared to the immediate post-procedural measurement. The calculation method involved subtracting the immediate post-procedural MLD from the follow-up MLD. A positive result (i.e., >0) indicated LLE, while a negative result (i.e., <0) indicated LLL. Measurements encompassed the entire treated segment plus 5 mm proximally and distally. Binary

restenosis was defined as stenosis of at least 50% of the luminal diameter at angiographic follow-up.

Statistical analysis:

The present trial's sample size was determined from our pilot study, where a 0.20 mm difference in the 6-month LLL change from baseline was observed across two randomized groups. Group sample sizes of 66 per group achieve 90% power to detect an LLL mean difference of 0.2 mm, a standard deviation of 0.4 mm in each group, and a significance level (alpha) of 0.05, using a two-sided two-sample equal-variance t-test. Considering the anticipated dropout rate, each group was planned to include 70 patients.

Statistical analysis was performed using SPSS software (version 25.0; SPSS Inc., Armonk, NY). Categorical variables are presented as the number of cases and percentages. Comparisons between groups were performed using the chi-square test. Continuous variables conforming to normal distributions are presented as the mean± standard deviation. Comparisons between groups were performed using the unpaired Student's t-test. Continuous variables not conforming to normal distributions are expressed as median (interquartile ranges). Between-group comparisons were processed using the Mann–Whitney U test.

Results

From May 2022 to January 2023, we recruited 235 patients with ACS who were hospitalized in Fuwai Central China Cardiovascular Hospital. Among them, two patients were lost to follow-up after randomization, one participant refused to return to hospital for endpoint assessment (Figure 1). A total of 137 patients (69 in the rivaroxaban group

and 68 in the control group) completed the treatment and endpoint assessments, of which 119 (90.15%) were male, with an average age of 50.72±6.49 years. All patients successfully underwent PCI using a DCB, with type A-C dissections (as classified by the NHLBI). All participants used the SeQuent DCB manufactured by B. Braun, Germany. No stents were used for any lesions during hospitalization. Baseline clinical characteristics, shown in Table 1, revealed that 32% had diabetes mellitus, and clinical indications were unstable angina (62%), and non-ST-segment elevation myocardial infarction (38%). The baseline characteristics were comparable between the two randomized groups.

Table 2 presents baseline angiographic and procedural characteristics, demonstrating comparability in RVD, lesion length, MLD, operation time, the use of scoring balloons for predilation. We found that the majority of the dissections were of Type A(69.3%), and the distribution of dissection types was similar in both groups, with no significant differences being observed.

Post-operative and follow-up stenosis analysis can be seen in Table 3. MLD at post-procedure was comparable in both groups, being 2.20 mm (IQR: 1.78-2.50) in the rivaroxaban group versus 2.23 mm (IQR: 1.7-2.53) in the control group (P = 0.690). The acute lumen gain was also comparable in both groups (P = 0.879). Patients underwent scheduled angiographic follow-up with quantitative coronary assessment after 190 days (IQR: 173-223 days). At follow-up, there was a noticeable difference in MLD between the rivaroxaban group and the control group (2.37 mm, IQR: 1.96-2.78 versus 2.16 mm, IQR: 1.75-2.41; P = 0.010). Meanwhile, a significant difference in net lumen gain

between the rivaroxaban group and the control group was observed (1.43 \pm 0.81 mm versus 1.16 \pm 0.59 mm, P = 0.024). The primary endpoint of LLL showed a significant difference between the rivaroxaban group and the control group (-0.12 \pm 0.56 mm versus 0.14 \pm 0.37 mm, P = 0.002) (Figure 4). Of note, this negative LLL rather represents a late lumen enlargement in rivaroxaban group.

During follow-up angiography, over 90% of the dissections in both groups healed completely, with 10 cases of persistent but uncomplicated dissections (Figure 2). There was no significant difference in the healing of dissections between the two groups.

Table 4 indicates more BARC type 1-2 bleeding events in the rivaroxaban group, suggesting minor bleeding events without an increased probability of major bleeding. One patient in the rivaroxaban group had a type 3a BARC bleeding event, resulting in a decrease in hemoglobin to 63 g/L and requiring blood transfusion. TVF occurred in 1 patient (1.5%) in the rivaroxaban group and in 4 patients (5.8%) in the control group, primarily due to TVR (Table 5, P = 0.354).

Discussion

This prospective study explored the impact of administering a low-dose rivaroxaban regimen for one months on imaging outcomes and clinical events in ACS patients with non-flow-limiting dissections following DCB intervention for de novo lesions. The key findings of this study are as follows: 1) The oral administration of low-dose rivaroxaban is associated with significant reduction in late lumen loss;2) Irrespective of rivaroxaban use, dissections tend to heal almost completely.

During the early era of balloon angioplasty (BA), the issue of vessel restenosis

posed a significant challenge, often attributed to inadequate predilatation. Increasing balloon diameter was an attempt to improve suboptimal predilatation, but it concurrently raised the probability of dissection occurrence. Early experiences revealed that, despite a very low occurrence of thrombotic events and an acceptable rate of restenosis (12%), 36.7% of dissections following BA were still visible at 6-month angiographic follow-up²⁰. In the case of DES edge dissections post-percutaneous coronary intervention, studies have demonstrated that dissections, particularly those with a smaller effective lumen area, are associated with target lesion revascularization during 1-year follow-up post-DES implantation²¹. However, in the DCB era, research by Cortese, et al. identified that dissections post-DCB intervention did not significantly correlate with restenosis or adverse events. Furthermore, a significant majority of dissections (94%) exhibited complete healing during follow-up angiography, irrespective of the dissection type²². These findings confirm the safety of non-flow-limiting dissections post-DCB intervention and underscore the potential of DCB in facilitating dissection healing.

In the DCB era, the presence of non-flow limiting dissections after DCB intervention was generally considered safe. In the third International DCB Consensus Report, the criteria for dissection management shifted from necessitating stent rescue for Type C-F dissections to those deemed as flow-limiting. Studies, including those by Yamamoto and Sogabe, have even suggested that dissections might predict late lumen enlargement²³. Potential mechanisms involve dissections increasing the contact area between the drug-coated balloon and the vessel, thus facilitating better utilization of

anti-proliferative agents like paclitaxel to inhibit intimal hyperplasia and promote vessel expansion. Furthermore, the disruption of the intima or media by dissections, influenced by hemodynamics, might contribute to further vessel dilation.

As a novel oral anticoagulant, rivaroxaban is the first direct factor Xa inhibitor, selectively targeting the active site of factor Xa. In addition to inhibiting the coagulation cascade, rivaroxaban also exerts antiplatelet effects by inhibiting platelet activation, which is mediated by FXa activation of the PAR-1 receptor, and by modulating PAR-1 and PAR-2 pathways involved in the inflammatory response^{24, 25}. Multiple studies have shown that low-dose rivaroxaban therapy in coronary heart disease is linked with lower rates of MACE, albeit with an elevated bleeding risk¹¹⁻¹³. Considering this, we established stringent exclusion criteria to omit patients at a relatively higher risk of bleeding from the study. Our observations indicated a marginally higher incidence of BARC 1-2 bleeding events (minor bleeding) in the rivaroxaban group compared to the control group, yet without an increase in major bleeding risk. However, large-scale studies with a larger sample size and longer follow-up time are needed to determine this result

In the setting of a spontaneous coronary section, although debatable, there are reports that antiplatelet can worsen outcomes. There are hypotheses that antithrombotic therapy can prolong the dissection by increasing the hematoma.²⁶ But, the pathophysiological mechanisms and the affected patient population of spontaneous coronary artery dissection (SCAD) differ significantly from the context of our study. Most SCAD patients are females, and there may be increased vasa vasorum density,

12

fibromuscular dysplasia, and other issues, leading to a higher risk of bleeding and different outcomes of administrating antithrombotic drugs.²⁷

In Cortese, et al.'s study, about one-third of the lesions treated with DCB for de novo lesions exhibited dissections, yet the majority of these dissections (94%) had healed completely during follow-up coronary angiography. These results are comparable to those in the present study, in which dissections healed completely in 92.7% (Figure 2). In the control group, lesions with dissections post-DCB treatment showed late lumen loss during follow-up angiography, measured at 0.14 ± 0.37 mm, comparable to the earlier study $(0.14 \pm 0.28 \text{ mm})^{22}$. However, the rivaroxaban group generally exhibited late lumen enlargement (Figure 3), with a late luminal enlargement of 0.12±0.56 mm. Compared to the control group, a significant increase in lumen diameter was observed (P = 0.01) (Table 3). Net lumen gain was also notably larger in the rivaroxaban group (P = (0.024). These results indicate that rivaroxaban significantly improved both the degree of stenosis and the late luminal gain in these lesions. Previous research observed late lumen enlargement post-DCB intervention may be associated with the reattachment and healing of the dissection flap, and the regression of the dissection flap²⁸. Reattachment and healing of the dissection flap were defined as the dissection flap protruding into the vessel lumen becoming reattached to the tunica media and healing. The regression of the dissection flap was defined as an obvious partial tissue loss in the dissection flap at follow-up, as compared to the post-PCI state. They discovered that the frequency of dissection flap regression was significantly higher in the LLE group (40.4% vs. 14.6%, p < 0.01). These observations suggest that promoting flap regression during the

dissection occurrence and healing process might lead to greater late lumen expansion. This necessitates the use of robust antithrombotic therapy to maintain blood flow, thus playing a crucial role in the interaction between dissections and vessels, and in turn, facilitating lumen enlargement. Rivaroxaban, with its anticoagulant and anti-inflammatory properties, maintained robust antithrombotic activity during the acute phase of dissection formation, especially when combined with dual antiplatelet therapy. This approach correspondingly promoted maximal lumen expansion. As observed in this study, combining rivaroxaban with dual antiplatelet therapy improved stenosis severity and facilitated late lumen expansion in patients with dissections post-DCB intervention. This approach has the potential to enhance coronary blood flow, improve myocardial perfusion, reduce cardiac event risk. Meanwhile, in the control group, a higher incidence of TVF was observed, though it did not reach statistical significance, underscoring the need for further large-scale studies for confirmation.

Study limitations

Several limitations should be acknowledged in our study. Firstly, observing dissections via angiography inherently carries subjectivity, as numerous subtle dissections may escape detection in angiographic images. Therefore, future research should employ more detailed and standardized evaluations using intravascular imaging techniques such as IVUS and OCT. Secondly, the limited sample size, single-center design, and brief follow-up period in our study highlight the need for more extensive, multicenter, and prolonged studies to validate the effects of oral rivaroxaban on dissections post-DCB intervention, including its long-term safety. Moreover, both

mechanistic studies and clinical trials are warranted to elucidate the underlying mechanisms and clinical potential of rivaroxaban in treating coronary heart disease.

CONCLUSIONS

This study demonstrates that the combination of rivaroxaban with dual antiplatelet therapy shows promise in reducing stenosis and enhancing late lumen expansion in lesions with dissections post-DCB intervention. However, additional studies are essential to corroborate these results and assess the long-term outcomes and safety of this combined therapeutic approach.

	Rivaroxaban group(n=69)	Control group(n=68)	Р
Male	59(85.5%)	60(88.2%)	0.637
Age, years	50.12±6.45	51.34±6.52	0.272
Hypertension	30(43.5%)	21 (30.9%)	0.127
Hypercholesterolemia	36(52.2%)	30 (44.1%)	0.345
Diabetes mellitus	9(13%)	16(23.5%)	0.112
History of smoking	40(58%)	36(52.9%)	0.554
History of drinking	30(43.5%)	29(42.6%)	0.922
BMI	30.89±10.93	32.10±11.66	0.535
Prior MI	7(10.1%)	4(5.8%)	0.359
Prior PCI	9(13%)	9(13.2%)	0.974
Haemoglobin(g/dL)	138.52 ± 13.46	140.53±15.29	0.416
Creatinine clearand	ce	94.38±14.52 89.908±12.678	0.069
(mL/min)	94.38114.32		
Clinical presentation			
Unstable angina	44(64%)	41(60%)	
Non-ST-segment elevation	on 25(36%)	27(40%)	0.675
MI			

Table1 Baseline characteristics of the participants

Values are mean±SD, median (interquartile ranges, 25th-75th), or n (%). MI, myocardial

infarction; PCI, percutaneous coronary intervention; CAD, coronary artery disease.

	Rivaroxaban group(n=69)	Control group (n=68)	Р
Reference vessel diameter, mm	3(2.7-3.65)	3.1(2.83-3.5)	0.406
Lesion length, mm	25(15.8-34.7)	23(15.7-32)	0.544
MLD, mm	0.89(0.61-1.2)	0.95(0.59-1.21)	0.628
Diameter stenosis	72.39±13.56	71.85±14.89	0.822
Predilation balloon to reference	1.00±0.16	0.97±0.12	0.201
vessel ratio			
Scoring balloon for predilation	60(86.9%)	63(92.6%)	0.272
Operation duration, min	90(64-120)	85(65-123.8)	0.889
Total length of DCB, mm	30(20-45)	26(20-30)	0.544
Maximum diameter of DCB, mm	3.04±0.51	3.08±0.51	0.567
Total occlusion	6(8.69%)	8(11.76%)	0.553
Type of dissection			
А	47(68.1%)	48(70.6%)	0.941
В	18(26.1%)	16(23.5%)	
С	4(5.8%)	4(5.9%)	
Target vessel			
Left anterior descending artery	26(37.7%)	36(52.9%)	0.200
Left circumflex artery	23(33.3%)	17(25%)	
Right coronary artery	20(29%)	15(22.1%)	

Table 2 : Angiographic and Procedural Characteristics

Values are mean±SD, median (interquartile ranges, 25th-75th), or n (%). DCB,

drug-coated balloon; MLD, minimum luminal diameter.

	Rivaroxaban group(n=69)	Control group (n=68)	Р
MLD at post-procedure,	2.20(1.78-2.50)	2.23(1.70-2.53)	0.690
Diameter stenosis at post-procedure	28.94±15.32	30.95±13.28	0.413
Acute lumen gain, mm	1.31±0.54	1.29±0.56	0.879
MLD at follow-up, mm	2.37(1.96-2.78)	2.16(1.75-2.41)	0.010
Diameter stenosis at follow-up	25.46 ±23.50	35.12±16.54	0.006
Late lumen Loss, mm	-0.12±0.56	0.14±0.37	0.002
Binary restenosis, mm	1(1.4%)	2(2.9%)	0.989
Net lumen gain, mm	1.43 ±0.81	1.16 ±0.59	0.024
Dissection at follow-up			
None	65(94.2%)	62(91.2%)	0.725
А	4(5.8%)	6(8.8%)	
В	0	0	
С	0	0	

Table 3: Analysis of Lesion Stenosis at Post-Procedure and Follow-Up

Values are mean±SD, median (interquartile ranges, 25th-75th), or n (%). MLD, minimum luminal diameter.

BARC	Bleeding	Rivaroxaban group(n=69)	Control group (n=68)	Р
Classification				
1		11(15.9%)	6(5.9%)	0.059
2		4(5.8%)	3(4.4%)	1
3a		1(1.4%)	0	NA
3b and higher		0	0	NA

Table 4: Bleeding Event Endpoints

Values are n (%). BARC, bleeding academic research consortium.

Table 5: Clinical Outcomes

	Rivaroxaban group(n=69)	Control group (n=68)	Р
Cardiac death	0	0	NA
Target vessel myocardial	0	0	NA
infarction			
Target vessel	1(1.5%)	4(5.8%)	0.354
revascularization			
Target vessel thrombosis	0	0	NA
Target vessel failure	1(1.35%)	4(5.8%)	0.354

Values are n (%). Target vessel failure consisted of cardiac death, target vessel

myocardial infarction, target vessel revascularization, and target vessel thrombosis.



Figure 1 flow diagram for the study



Figure 2 The Fate of Dissections After DCB Angioplasty

Figure shows what happened to dissections at 6-month angiography: Over 90% of the dissections remaining post-DCB in both groups healed completely, with 10 cases of persistent but uncomplicated dissections .



Figure 3 Cumulative frequency distribution curves of minimal lumen diameter of rivaroxaban group (a) and Control group (b) before procedure, after procedure, and at follow-up.



Figure 4 Comparison of late lumen loss

References:

1. Ali RM, Abdul Kader MASK, Wan Ahmad WA, et al. Treatment of Coronary Drug-Eluting Stent Restenosis by a Sirolimus- or Paclitaxel-Coated Balloon. *JACC: Cardiovascular Interventions*. 2019;12(6):558-566.

2. Naganuma T, Latib A, Sgueglia GA, et al. A 2-year follow-up of a randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels the BELLO study. *Int J Cardiol.* 2015;184:17-21.

3. Jeger RV, Eccleshall S, Wan Ahmad WA, et al. Drug-Coated Balloons for Coronary Artery Disease: Third Report of the International DCB Consensus Group. *JACC. Cardiovascular interventions*. 2020;13(12):1391-1402.

4. Scheller B, Ohlow M, Ewen S, et al. Bare metal or drug-eluting stent versus drug-coated balloon in non-ST-elevation myocardial infarction: the randomised PEPCAD NSTEMI trial. *EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.* 2020;15(17):1527-1533.

5. Nestelberger T, Kaiser C, Jeger R. Drug-coated balloons in cardiovascular disease: benefits, challenges, and clinical applications. *Expert Opin Drug Deliv.* 2020;17(2):201-211.

6. Kuwabara K, Zen K, Yashige M, et al. Comparative Analysis of the Paclitaxel-Eluting Peripheral Igaki-Tamai Stent and the Drug-Free Igaki-Tamai Stent Using Optical Coherence Tomography and Histological Analysis in a Porcine Iliac Artery Model. *Circulation journal : official journal of the Japanese Circulation Society*. 2020;84(5):799-805.

7. Venetsanos D, Lawesson SS, Panayi G, et al. Long-term efficacy of drug coated balloons compared with new generation drug-eluting stents for the treatment of de novo coronary artery lesions. *Catheter Cardiovasc Interv.* 2018;92(5):E317-E326.

8. Rissanen TT, Uskela S, Eränen J, et al. Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial. *Lancet (London, England)*. 2019;394(10194):230-239.

9. Widder JD, Cortese B, Levesque S, et al. Coronary artery treatment with a urea-based paclitaxel-coated balloon: the European-wide FALCON all-comers DCB Registry (FALCON Registry). *EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.* 2019;15(4):e382-e388.

10. Nakagama S, Niida T, Matsuda Y, et al. 6111Optical coherence tomography derived predictors of restenosis after non-stenting coronary intervention with drug-coated balloon. *Eur Heart J*. 2019;40(Supplement_1):ehz137-ehz746.

11. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. *N Engl J Med.* 2017;377(14):1319-1330.

12. Ohman EM, Roe MT, Steg PG, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. *Lancet.* 2017;389(10081):1799-1808.

13. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. *N Engl J Med.* 2012;366(1):9-19.

14. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ (Clinical research ed.).* 2010;340:c332.

15. Urban P, Mehran R, Colleran R, et al. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. *Circulation*. 2019;140(3):240-261.

16. Her A, Shin E, Bang LH, et al. Drug-coated balloon treatment in coronary artery disease: Recommendations from an Asia-Pacific Consensus Group. *Cardiol J.* 2021;28(1):136-149.

17. Huber MS, Mooney JF, Madison J, Mooney MR. Use of a morphologic classification to predict clinical outcome after dissection from coronary angioplasty. *The American journal of cardiology*. 1991;68(5):467-471.

18. Hicks KA, Tcheng JE, Bozkurt B, et al. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). *Circulation*. 2015;132(4):302-361.

19. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. *Circulation*. 2011;123(23):2736-2747.

20. Cappelletti A, Margonato A, Rosano G, et al. Short- and long-term evolution of unstented nonocclusive coronary dissection after coronary angioplasty. *J Am Coll Cardiol*. 1999;34(5):1484-1488.

21. Kobayashi N, Mintz GS, Witzenbichler B, et al. Prevalence, Features, and Prognostic Importance of Edge Dissection After Drug-Eluting Stent Implantation: An ADAPT-DES Intravascular Ultrasound Substudy. *Circulation. Cardiovascular interventions.* 2016;9(7):e3553.

22. Cortese B, Silva Orrego P, Agostoni P, et al. Effect of Drug-Coated Balloons in Native Coronary Artery Disease Left With a Dissection. *JACC. Cardiovascular interventions*. 2015;8(15):2003-2009.

23. Yamamoto T, Sawada T, Uzu K, Takaya T, Kawai H, Yasaka Y. Possible mechanism of late lumen enlargement after treatment for de novo coronary lesions with drug-coated balloon. *Int J Cardiol.* 2020;321:30-37.

24. Goto M, Miura S, Suematsu Y, et al. Rivaroxaban, a factor Xa inhibitor, induces the secondary prevention of cardiovascular events after myocardial ischemia reperfusion injury in mice. *Int J Cardiol.* 2016;220:602-607.

25. Esmon CT. Targeting factor Xa and thrombin: impact on coagulation and beyond. *Thromb Haemost.* 2014;111(4):625-633.

26. Cerrato E, Giacobbe F, Quadri G, et al. Antiplatelet therapy in patients with conservatively managed spontaneous coronary artery dissection from the multicentre DISCO registry. *Eur Heart J*. 2021;42(33):3161-3171.

27. Saw J, Mancini GBJ, Humphries KH. Contemporary Review on Spontaneous Coronary Artery Dissection. *J Am Coll Cardiol.* 2016;68(3):297-312.

28. Sogabe K, Koide M, Fukui K, et al. Optical coherence tomography analysis of late lumen enlargement after paclitaxel-coated balloon angioplasty for de-novo coronary artery disease. *Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.* 2021;98(1):E35-E42.